Spots Global Cancer Trial Database for A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes
Official Title: A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes
Study ID: NCT00458159
Conditions
Interventions
Study Description
Brief Summary: A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Indiana University Medical Center, Indianapolis, Indiana, United States
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
New York Presbyterian Hospital-Weill Cornell Medical College, New York, New York, United States
Wake Forest University School of Medicine Bowman Gray Campus, Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Alan List, MD
Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
